(Q37768952)

22 August 2017

title

Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness (English)

1 reference

22 August 2017

5

0 references

Andrew M Luks

1

object named as

Andrew M Luks

1 reference

22 August 2017

Scott E McIntosh

2

1 reference

22 August 2017

Colin K Grissom

3

1 reference

22 August 2017

Paul S Auerbach

4

1 reference

22 August 2017

Robert B Schoene

6

1 reference

22 August 2017

Ken Zafren

7

1 reference

22 August 2017

Peter H Hackett

8

1 reference

22 August 2017

Wilderness Medical Society

9

1 reference

22 August 2017

language of work or name

1 reference

10 March 2010

1 reference

Wilderness and Environmental Medicine

22 August 2017

published in

1 reference

22 August 2017

volume

21

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

146-155

1 reference

Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

7 January 2021

High-Altitude Illness

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

High altitude cerebral edema.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Illnesses at high altitude

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Effect of ascent protocol on acute mountain sickness and success at Muztagh Ata, 7546 m.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Effect of six days of staging on physiologic adjustments and acute mountain sickness during ascent to 4300 meters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

The incidence, importance, and prophylaxis of acute mountain sickness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Effect of acetazolamide on acute mountain sickness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Prophylactic low-dose acetazolamide reduces the incidence and severity of acute mountain sickness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Children at high altitude: an international consensus statement by an ad hoc committee of the International Society for Mountain Medicine, March 12, 2001.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

A randomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollagüe (3696 m) in northern Chile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Ginkgo biloba does--and does not--prevent acute mountain sickness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Treatment of acute mountain sickness by simulated descent: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Simulated descent v dexamethasone in treatment of acute mountain sickness: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Acetazolamide in the treatment of acute mountain sickness: clinical efficacy and effect on gas exchange.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Dexamethasone in the treatment of acute mountain sickness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Update on high-altitude pulmonary edema: pathogenesis, prevention, and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Physiological aspects of high-altitude pulmonary edema

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Pulmonary extravascular fluid accumulation in climbers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

HIGH-ALTITUDE PULMONARY OEDEMA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Prevention of high-altitude pulmonary edema by nifedipine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Salmeterol for the prevention of high-altitude pulmonary edema.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Acetazolamide prevents hypoxic pulmonary vasoconstriction in conscious dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Effects of acetazolamide on ventilatory, cerebrovascular, and pulmonary vascular responses to hypoxia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Evaluation of therapeutic methods in high altitude pulmonary edema

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Treatment of high-altitude pulmonary edema by bed rest and supplemental oxygen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Use of the Gamow Bag by EMT-basic park rangers for treatment of high-altitude pulmonary edema and high-altitude cerebral edema.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Nifedipine for high altitude pulmonary oedema

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

Treatment of high altitude pulmonary edema at 4240 m in Nepal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

High altitude pulmonary edema and exercise at 4,400 meters on Mount McKinley. Effect of expiratory positive airway pressure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WEM.2010.03.002

10.1016/J.WEM.2010.03.002

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference